A comprehensive and collaborative strategy to enable the investigation of new uses of approved and abandoned drug compounds could advance translational research.
“Please read this paper; it is an interesting initiative to get drugs off the shelves of Pharma companies and into the hands of investigators and hopefully into clinical trials. The biggest potential benefit of this will be progressive MS’ers. If big Pharma have gone cold on progressive MS, we certainly haven’t.”
Cannot read the article without paying the publisher for the privilege.Can you please distil its content for us?
That was my first impression but it's free if you register. I read it